Exploring metabolic features in melanoma
Identification of Metabolic Phenotypes Associated With Prognosis and Therapeutic Response in Patients With Melanoma
This study is testing how melanoma affects the way the body processes sugar by looking at tissue and blood samples from patients to better understand the disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peter MacCallum Cancer Centre, Australia Academic / other |
| Locations | 1 site (Melbourne, Victoria) |
| Trial ID | NCT05570227 on ClinicalTrials.gov |
What this trial studies
This study investigates the metabolic characteristics of melanoma by collecting tissue samples from patients undergoing surgical excision or biopsy. It involves administering a stable isotope, [U-13C]Glucose, to a subset of patients to analyze how glucose metabolism is altered in melanoma. Blood samples will be taken to monitor glucose levels and assess the enrichment of labeled nutrients using advanced mass spectrometry techniques. The study aims to correlate metabolic findings with clinical and genomic data to enhance understanding of melanoma biology.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a known melanoma lesion requiring surgical intervention.
Not a fit: Patients with diabetes, those who are pregnant or breastfeeding, or individuals unable to comply with study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for melanoma patients based on their metabolic profiles.
How similar studies have performed: While metabolic profiling in cancer is an emerging field, this specific approach using [U-13C]Glucose infusion in melanoma is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient has provided written informed consent 2. Male or female aged 18 years or older at written informed consent 3. Presence of a known melanoma lesion requiring surgical excision or biopsy 4. Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies and receiving a stable isotope infusion (where applicable) Exclusion Criteria: Patients who meet any of the following criteria will be excluded from receiving a \[U-13C\]Glucose infusion: 1. Diabetes mellitus 2. Pregnancy or breast feeding 3. Patients unable to comply with study procedures and follow up in the opinion of the investigator
Where this trial is running
Melbourne, Victoria
- Peter Mac Callum Cancer Centre — Melbourne, Victoria, Australia (Recruiting)
Study contacts
- Principal investigator: Aparna Rao, MBBS PhD — Peter MacCallum Cancer Centre, Australia
- Study coordinator: Aparna Rao
- Email: aparna.rao@petermac.org
- Phone: +61385595000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.